Neurosurgical Review

, Volume 11, Issue 3–4, pp 267–272 | Cite as

The proliferation rate of intracranial tumors as defined by the monoclonal antibody KI 67. Application of the method to paraffin embedded specimens

  • Dieter-Karsten Böker
  • Heinz-Jürgen Stark


60 intracranial tumors have been studied immunohistochemically to determine the proliferation rate by staining for the monoclonal antibody KI-67, which recognizes a nuclear antigen expressed by cells in proliferation. In gliomas a clear correlation of stained nuclei to the histologically determined degree of malignancy was found: slow growing astrocytomas and oligodendrogliomas had an average proliferation rate of 1%, more malignant forms of 7–10%. Glioblastomas were found to have a growth fraction of 15%. Metastases had an even higher rate of 20% proliferating cells. In meningiomas the proliferation rate was mainly about 1%, but in three cases it was between 5% and 7%. Whether this is indicative for a higher risk of tumor recurrence, remains to be correlated to the clinical course. Hemangiopericytomas had a proliferation rate of 9% and 16%, respectively, the latter recurring within four months. It may be concluded from the results of this study, that investigation of intracranial tumors with KI 67 may be of prognostic value and can possibly contribute to an individualized tumor therapy.


Brain tumors immunohistochemistry KI 67 proliferation rate 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Adegbite, AB, MI Khan, KWE Paine, LK Tan: The recurrence of intracranial meningiomas after surgical treatment. J Neurosurg 58 (1983) 51–56Google Scholar
  2. [2]
    Böker DK, H Meurer, F Gullotta: Recurring intracranial meningiomas. Evaluation of some factors predisposing for tumor recurrence. J Neurosurg Sci 29 (1985) 11–17Google Scholar
  3. [3]
    Burger PC, RT Vollmer: Histologic factors of prognostic significance in the glioblastoma multiforme. Cancer 46 (1980) 1179–1186Google Scholar
  4. [4]
    Burger PC, T Shibata, P Kleihues: The use of the monoclonal antibody KI 67 in the identification of proliferating cells: application to surgical neuropathology. Am J Surg Pathol 10 (1986) 611–617Google Scholar
  5. [5]
    Crompton RM, PC Gautier-Smith: The prediction of recurrence in meningiomas. J Neurol Neurosurg Psychiat 33 (1970) 80–87Google Scholar
  6. [6]
    Gerdes, J, U Schwab, H Lemke, H Stein: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31 (1983) 13–20Google Scholar
  7. [7]
    Gerdes J, F Dallenbach, K Lennert: Growth fractions in malignant non-Hodgkin's lymphomas (NHL) as determined in situ with the monoclonal antibody KI-67. Hematol Oncol 2 (1984) 365–371Google Scholar
  8. [8]
    Gerdes J, H Lemke, H Baisch, HH Wacker, U Schwab, H Stein: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody KI-67. J Immunol 133 (1984) 1710–1715Google Scholar
  9. [9]
    Giangaspero F, PC Burger: Correlations between cytologic composition and biologic behaviour in the glioblastoma multiforme. A postmortem study of 50 cases. Cancer 52 (1983) 2320–2333Google Scholar
  10. [10]
    Giangaspero F, C Doglioni, MT Rivano, S Pileri, J Gerdes, H Stein: Growth fraction in human brain tumors defined by the monoclonal antibody KI-67. Acta Neuropathol (Berl) 74 (1987) 179–182Google Scholar
  11. [11]
    Hoshino T, M Barker, CB Wilson, EB Boldrey, D Fewer: Cell kinetics of human gliomas. J Neurosurg 37 (1972) 15–26Google Scholar
  12. [12]
    Hoshino T, CB Wilson, ML Rosenblum, M Barker: Chemotherapeutic implications of growth fraction and cell cycle time in glioblastomas. J Neurosurg 43 (1975) 127–135Google Scholar
  13. [13]
    Hoshino T, CB Wilson: Cell kinetic analysis of human malignant brain tumors (gliomas). Cancer 44 (1979) 956–962Google Scholar
  14. [14]
    Hoshino T, T Nagashima, JA Murovic, CB Wilson, MSB Edwards, PH Gutin, RL Davis, SJ DeArmond: In situ cell kinetics studies on human neuroectoderma tumors with bromodeoxyuridine labeling. J Neurosurg 64 (1986) 453–459Google Scholar
  15. [15]
    Johnson HA, WE Haymaker, JR Rubini, TM Fliedner, VP Bond, EP Cronkite, WL Hughes: A radioautographic study of a human glioblastoma multiforme after the in vivo uptake of tritiated thymidine. Cancer 13 (1960) 636–642Google Scholar
  16. [16]
    Kury G, HW Carter: Autoradiographic study of human nervous system tumors. Arch Path 80 (1965) 38–42Google Scholar
  17. [17]
    Lloyd RV, BS Wilson, J Varani, PK Gaur, S Moline, JG Makari: Immunocytochemical characterization of a monoclonal antibody that recognizes mitosing cells. Am J Pathol 121 (1985) 275–283Google Scholar
  18. [18]
    Malaise EP, N Chavaudra, M Tubiani: The relationship between growth rate, labelling index and histological type of human solid tumors. Europ J Cancer 9 (1973) 305–312Google Scholar
  19. [19]
    Melamed S, A Sahar, AJ Beller: The recurrence of intracranial meningiomas. Neurochirurgia 22 (1979) 47–51Google Scholar
  20. [20]
    Nagashima T, SJ DeArmond, J Murovic, T Hoshino: Immunocytochemical demonstration of Sphase cells by anti-bromodeoxyuridine monoclonal antibody in human brain tumor tissues. Acta Neuropathol (Berl) 67 (1985) 155–159Google Scholar
  21. [21]
    Roggendorf W, T Schuster, J Peiffer: Proliferative potential of meningiomas determined with the monoclonal antibody KI-67. Acta Neuropathol (Berl) 73 (1987) 361–364Google Scholar
  22. [22]
    Sato Y, K Mukai, S Watanabe, M Goto, Y Shimosato: The AMeX method. A simplified technique if tissue processing and paraffin embedding with proved preservation of antigens for immunostaining. Am J Pathol 125 (1986) 431–435Google Scholar
  23. [23]
    Yamashita J, H Handa, K Iwaki, M Abe: Recurrence of intracranial meningiomas, with special reference to radiotherapy. Surg Neurol 14 (1980) 33–40Google Scholar

Copyright information

© Walter de Gruyter & Co. 1988

Authors and Affiliations

  • Dieter-Karsten Böker
    • 1
    • 2
  • Heinz-Jürgen Stark
    • 1
  1. 1.Neurosurgical University ClinicBonnWest Germany
  2. 2.Neurochirurgische Univ.-KlinikBonn 1West Germany

Personalised recommendations